POTASSIUM CITRATE EXTENDED RELEASE: Package Insert and Label Information (Page 2 of 2)

14.3 Uric Acid Lithiasis with or without Calcium Stones

A long-term non-randomized, non-placebo controlled clinical trial with eighteen adult patients with uric acid lithiasis participated in the study. Six patients formed only uric acid stones, and the remaining 12 patients formed mixed stones containing both uric acid and calcium salts or formed both uric acid stones (without calcium salts) and calcium stones (without uric acid ) on separate occasions.

Eleven of the 18 patients received potassium citrate alone. Six of the 7 other patients also received allopurinol for hyperuricemia with gouty arthritis, symptomatic hyperuricemia, or hyperuricosuria. One patient also received hydrochlorothiazide because of unclassified hypercalciuria. The main inclusion criterion was a history of stone passage or surgical removal of stones during the 3 years prior to initiation of potassium citrate therapy. All patients received potassium citrate at a dosage of 30-80 mEq/day in three-to-four divided doses and were followed every four months for up to 5 years.

While on potassium citrate treatment, urinary pH rose significantly from a low value of 5.3 ± 0.3 to within normal limits (6.2 to 6.5). Urinary citrate which was low before treatment rose to the high normal range and only one stone was formed in the entire group of 18 patients.

15 REFERENCES

1. Pak, C. (1987). Citrate and Renal Calculi. Mineral and Electrolyte Metabolism 13 , 257-266.

2. Pak, C. (1985). Long-Term Treatment of Calcium Nephrolithiasis with Potassium Citrate. The Journal of Urology 134 , 11-19.

3. Preminger, G.M., K. Sakhaee, C. Skurla and C.Y.C. Pak. (1985). Prevention of Recurrent Calcium Stone Formation with Potassium Citrate therapy in Patients with Distal Renal Tubular Acidosis. The Journal of Urology 134 , 20-23.

4. Pak, C.Y.C., K. Sakhaee and C. Fuller. (1986). Successful Management of Uric Acid Nephrolithiasis with Potassium Citrate. Kidney International 30 , 422-428.

5. Hollander-Rodriguez, J et al. (2006). Hyperkalemia, American Family Physician , Vol.73/No. 2.

6. Greenberg, A et al. (1998). Hyperkalemia: treatment options. Semen Nephrol. Jan; 18 (1): 46-57.

16 HOW SUPPLIED/STORAGE AND HANDLING

Potassium citrate extended-release tablets USP 5 mEq are uncoated, pale yellow colored, round shaped, bi-Convex, debossed with ‘S406’ on one side and plain on the other side, supplied in bottles as:

NDC 42543-406-01 Bottle of 100 tablets

Potassium citrate extended-release tablets USP 10 mEq are uncoated, pale yellow colored, caplet shaped, bi-Convex, debossed with ‘S407’ on one side and plain on the other side, supplied in bottles as:

NDC 42543-407-01 Bottle of 100 tablets

Potassium citrate extended-release tablets USP 15 mEq are uncoated, pale yellow colored, caplet shaped, bi-Convex, debossed with ‘S408’ on one side and plain on the other side, supplied in bottles as:

NDC 42543-408-01 Bottle of 100 tablets

Storage: Store in a tight container at 20°–25°C (68°–77°F), Excursions permitted between 15° and 30°C (59° and 86°F) [See USP controlled room temperature].

17 PATIENT COUNSELING INFORMATION

17.1 Administration of Drug

Tell patients to take each dose without crushing, chewing or sucking the tablet.

Tell patients to take this medicine only as directed. This is especially important if the patient is also taking both diuretics and digitalis preparations.

Tell patients to check with the doctor if there is trouble swallowing tablets or if the tablet seems to stick in the throat.

Tell patients to check with the doctor at once if tarry stools or other evidence of gastrointestinal bleeding is noticed. Tell patients that their doctor will perform regular blood tests and electrocardiograms to ensure safety.

Manufactured by:

Strides Pharma Science Ltd.

Puducherry – 605014, India

Distributed by:

Strides Pharma Inc.

East Brunswick, NJ 08816

Revised: 01/2022

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Package Label — Principle Display Panel — 100 — Count Bottle, 5 mEq (540 mg)Tablets

NDC 42543-406 -01

100 Tablets

Potassium Citrate Extended-Release Tablets, USP

5 mEq (540 mg)per tablet

Rx only

Strides Pharma Inc.

5 mEq label
(click image for full-size original)

Package Label — Principle Display Panel — 100 — Count Bottle, 10 mEq (1080 mg)Tablets

NDC 42543-407 -01

100 Tablets

Potassium Citrate Extended-Release Tablets, USP

10 mEq (1080 mg)per tablet

Rx only

Strides Pharma Inc.

10 mEq label
(click image for full-size original)

Package Label — Principle Display Panel — 100 — Count Bottle, 15 mEq (1620 mg)Tablets

NDC 42543-408 -01

100 Tablets

Potassium Citrate Extended-Release Tablets, USP

15 mEq (1620 mg)per tablet

Rx only

Strides Pharma Inc.

15 mEq label
(click image for full-size original)
POTASSIUM CITRATE EXTENDED RELEASE potassium citrate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42543-406
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POTASSIUM CITRATE (ANHYDROUS CITRIC ACID) POTASSIUM CITRATE 5 meq
Inactive Ingredients
Ingredient Name Strength
CARNAUBA WAX
STEARIC ACID
MAGNESIUM STEARATE
Product Characteristics
Color YELLOW (PALE YELLOW) Score no score
Shape ROUND (ROUND SHAPED) Size 10mm
Flavor Imprint Code S;406
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42543-406-01 100 TABLET in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA206813 11/01/2017
POTASSIUM CITRATE EXTENDED RELEASE potassium citrate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42543-407
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POTASSIUM CITRATE (ANHYDROUS CITRIC ACID) POTASSIUM CITRATE 10 meq
Inactive Ingredients
Ingredient Name Strength
CARNAUBA WAX
STEARIC ACID
MAGNESIUM STEARATE
Product Characteristics
Color YELLOW (PALE YELLOW) Score no score
Shape CAPSULE (CAPLET SHAPED) Size 19mm
Flavor Imprint Code S;407
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42543-407-01 100 TABLET in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA206813 11/01/2017
POTASSIUM CITRATE EXTENDED RELEASE potassium citrate tablet
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:42543-408
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
POTASSIUM CITRATE (ANHYDROUS CITRIC ACID) POTASSIUM CITRATE 15 meq
Inactive Ingredients
Ingredient Name Strength
CARNAUBA WAX
STEARIC ACID
MAGNESIUM STEARATE
Product Characteristics
Color YELLOW (PALE YELLOW) Score no score
Shape CAPSULE (CAPLET SHAPED) Size 22mm
Flavor Imprint Code S;408
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:42543-408-01 100 TABLET in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA206813 11/01/2017
Labeler — Strides Pharma Inc. (078310501)
Establishment
Name Address ID/FEI Operations
Strides Pharma Science Limited 871402375 ANALYSIS (42543-406), ANALYSIS (42543-407), ANALYSIS (42543-408), MANUFACTURE (42543-406), MANUFACTURE (42543-407), MANUFACTURE (42543-408), PACK (42543-406), PACK (42543-407), PACK (42543-408)

Revised: 01/2022 Strides Pharma Inc.

Page 2 of 2 1 2

DrugInserts.com provides trustworthy package insert and label information about marketed drugs as submitted by manufacturers to the US Food and Drug Administration. Package information is not reviewed or updated separately by DrugInserts.com. Every individual package label entry contains a unique identifier which can be used to secure further details directly from the US National Institutes of Health and/or the FDA.

As the leading independent provider of trustworthy medication information, we source our database directly from the FDA's central repository of drug labels and package inserts under the Structured Product Labeling standard. Our material is not intended as a substitute for direct consultation with a qualified health professional.

Terms of Use | Copyright © 2023. All Rights Reserved.